GlassScriptPhysician profile
Stephen L Curtin
NPI 1609877596
$182.86
in general payments reported to CMS, 2019-2025
5 companies · $48.93 in 2025
The $48.93 reported for 2025 was less than what a typical Orthopaedic Surgery of The Spine provider received nationally (typical 2025 total: $2,116).
See the full distribution for Orthopaedic Surgery of the Spine
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $17.71 · 2021: $102 · 2023: $14.32 · 2025: $48.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $63.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $63.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Therapeutics, INC. | $84.59 | 2020-2021 | |
| Glaukos Corporation | $48.93 | 2025 | Idosetr, Istent Infinite |
| Smith+Nephew, INC. | $35.02 | 2021 | |
| Kci USA, INC. | $14.32 | 2023 | V.A.C. Veraflo Cleanse Choice, Prevena, V.A.C. Dermatac |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2,185,224.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Curtin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.